Belite Bio (BLTE) Q2 FY26 earnings call

Belite Bio achieved a significant milestone with the FDA's acceptance of the Tinlarebant NDA for Stargardt disease under Priority Review, targeting a February 2027 PDUFA date. The company is well-funded for commercialization and pipeline development, despite increased operating expenses driven by R&D milestones and pre-commercial preparations. Management is focused on the regulatory process while also advancing its pediatric and geographic atrophy programs.